secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2026-03-13T23:59:59+00:00
Accession:  0001104659-26-027390
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus ups at-the-market equity facility to $200M from $100M
------------------------------------------------------------

- Amended Sales Agreement with Jefferies allows up to $200M in common stock sales, increased from $100M.
- No shares sold under prior $100M agreement; new ATM offering uses customary terms.
- Jefferies to receive up to 3.0% commission; agreements include representations and indemnification.
- Prospectus supplement filed; sales may be in negotiated, block, or ATM transactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000110465926027390/0001104659-26-027390-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000110465926027390/tm268518d4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-027390

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer